De-escalation of IBD Therapy: When, Who, and How?

被引:5
作者
Waljee, Akbar K. [1 ,2 ,3 ]
Chaisidhivej, Natapat [4 ]
Saini, Sameer D. [1 ,2 ,3 ]
Higgins, Peter D. R. [3 ]
机构
[1] VA Ctr Clin Management Res, Ann Arbor, MI USA
[2] Univ Michigan, Med Sch, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Ann Arbor, MI USA
[4] Mahidol Univ, Bangkok, Thailand
关键词
D O I
10.1093/crocol/otz008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
When patients with inflammatory bowel disease reach clinical remission with biologic therapy, a question that often comes up is, "when can I stop my biologic medication?" This is a question fraught with challenges for both physicians and patients. For physicians, there are valid concerns that stepping down from a successful therapy will lead to relapse and disease exacerbation, and that stepping down could lead to anti-biologic antibodies. For patients, the question is often driven by concerns about long-term side effects and costs of biologics. This review provides an overview of the rationale for, and risks of, withdrawal of IBD therapy. Selected studies have shown how to identify subsets of patients in whom de-escalation can be performed with low risk of relapse. Practical guidance on when and how to de-escalate IBD therapy is provided.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] De-escalation of dose-intensified anti-TNF therapy in IBD patients in sustained deep remission
    Chu, I.
    Little, R.
    Sparrow, M.
    Ward, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S430 - S431
  • [32] De-escalation therapy in ventilator-associated pneumonia
    Niederman, Michael S.
    CURRENT OPINION IN CRITICAL CARE, 2006, 12 (05) : 452 - 457
  • [33] De-escalation of medical therapy in inflammatory bowel disease
    Gomes, Catarina Frias
    Chapman, Thomas P.
    Satsangi, Jack
    CURRENT OPINION IN PHARMACOLOGY, 2020, 55 : 73 - 81
  • [34] De-escalation versus shortening of dual antiplatelet therapy
    Galli, Mattia
    Costa, Francesco
    Navarese, Eliano Pio
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (04) : 267 - 269
  • [35] De-escalation therapy in ventilator-associated pneumonia
    Rello, J
    Vidaur, L
    Sandiumenge, A
    Rodríguez, A
    Gualis, B
    Boque, C
    Diaz, E
    CRITICAL CARE MEDICINE, 2004, 32 (11) : 2183 - 2190
  • [36] De-escalation and escalation of breast cancer treatment
    Smith, I.
    BREAST, 2017, 32 : S3 - S3
  • [37] De-constructing de-escalation
    Huttner, B.
    Pulcini, C.
    Schouten, J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (12) : 958 - 959
  • [38] Preparation, escalation, de-escalation, and normal activities
    Sadeghipour, Parham
    Mohebbi, Bahram
    Mousavizadeh, Mostafa
    Hosseini, Saeid
    Maleki, Majid
    JOURNAL OF CARDIAC SURGERY, 2021, 36 (05) : 1641 - 1643
  • [39] Frequency and effectiveness of dose de-escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA
    Rubin De Celix, C.
    Ricart, E.
    Martin-Arranz, M. D.
    de Francisco, R.
    Barrio, J.
    Mesonero, F.
    Gomollon, F.
    de Castro, L.
    Ramos, L.
    Garcia-Lopez, S.
    Arias, L.
    Manosa, M.
    Iglesias, E.
    Calvet, X.
    Pascual, I.
    Casanova, M. J.
    Perez-Calle, J. L.
    Giordano, A.
    Sierra, M.
    Vera, I.
    Navarro-Llavat, M.
    Lorente, R.
    Piqueras, M.
    Rivero, M.
    Guardiola, J.
    Esteve, M.
    Coronel, A. Fuentes
    Rodriguez-Lago, I.
    Ponferrada, A.
    Ber, Y.
    Tardillo, C.
    Marquez, L.
    Carpio, D.
    Taxonera, C.
    Bermejo, F.
    Busquets, D.
    Camps, B.
    Domenech, E.
    Chaparro, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1557 - I1559
  • [40] De-escalation of commitment in software projects: Who matters? What matters?
    Heng, CS
    Tan, BCY
    Wei, KK
    INFORMATION & MANAGEMENT, 2003, 41 (01) : 99 - 110